Affinage

Showing PRDX2 — PRP is a alias.

PRDX2

Peroxiredoxin-2 · UniProt P32119

Length
198 aa
Mass
21.9 kDa
Annotated
2026-06-10
100 papers in source corpus 22 papers cited in narrative 22 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

PRDX2 is a cytosolic thioredoxin-dependent 2-Cys peroxiredoxin that reduces hydrogen peroxide and thereby governs intracellular ROS homeostasis, a role first established by its sequence homology to yeast thioredoxin peroxidase (PMID:7607688) and by loss-of-function studies showing that PRDX2 depletion or knockout raises ROS and sensitizes cells to oxidative apoptosis (PMID:12943237, PMID:15259009). Its catalytic cycle is distinguished from that of PRDX1 by an unusually slow resolution (disulfide-formation) step (~0.2 s⁻¹ vs 11 s⁻¹), which prolongs the lifetime of the peroxidatic-cysteine sulfenic acid and permits formation of mixed disulfides with partner protein thiols, providing a biochemical basis for redox relay signaling (PMID:30284335). Through its ROS-buffering activity PRDX2 controls thymocyte development and proliferation (PMID:15259009) and regulates innate/adaptive immune effectors including TLR4 and BAFF (PMID:18442801). Beyond peroxidase chemistry, PRDX2 acts through direct protein interactions: it binds HIF-1α and HIF-2α and, upon nuclear translocation during prolonged hypoxia, blocks their binding to hypoxia-response elements independently of its enzymatic activity (PMID:26837221), and it binds RPL4 to displace MDM2, accelerating p53 ubiquitination and degradation to promote proliferation (PMID:34117220). PRDX2 has context-dependent roles in cancer: it is an epigenetically silenced tumor suppressor in AML whose loss drives ROS-dependent myeloid leukemogenesis and which participates in a CDK2-PRDX2 differentiation-blocking axis (PMID:22207736, PMID:29720484), yet in solid tumors it acts as a pro-survival factor supporting PI3K/AKT signaling, EMT, and chemoresistance (PMID:28432271, PMID:40217291). Its expression is transcriptionally driven by NF-κB-p65 during H. pylori infection (PMID:31536951) and modulated by DNMT3A mutations and the c-Myc/miR-200b-3p axis (PMID:30245403, PMID:29258530). PRDX2 is also secreted in erythroid exosomes where extracellular PRDX2 promotes osteoclastogenesis (PMID:33587325).

Mechanistic history

Synthesis pass · year-by-year structured walk · 15 steps
  1. 1995 Medium

    Established the molecular identity of PRDX2 as a thioredoxin-dependent peroxide reductase and placed it in the genome, defining the gene as an antioxidant enzyme.

    Evidence PCR cloning of human cDNA with sequence homology to yeast thioredoxin peroxidase, FISH and somatic cell hybrid mapping to 13q12

    PMID:7607688

    Open questions at the time
    • No direct enzymatic assay of the human protein in this study
    • Cellular function not addressed
  2. 2003 Medium

    Showed that PRDX2 protects cells against oxidative death, moving from inferred enzymatic identity to a defined cytoprotective cellular role.

    Evidence Stable antisense knockdown in SH-SY5Y neuroblastoma cells with apoptosis and oxidative-stress sensitivity assays

    PMID:12943237

    Open questions at the time
    • Antisense specificity limits mechanistic interpretation
    • Did not identify ROS targets or downstream signaling
  3. 2004 High

    Demonstrated in vivo that PRDX2 controls developmental and proliferative decisions through ROS, establishing it as a physiological ROS rheostat rather than a passive scavenger.

    Evidence PrxII-null mouse with flow cytometry of thymocyte subsets, apoptosis and proliferation readouts

    PMID:15259009

    Open questions at the time
    • Direct molecular ROS targets in thymocytes not defined
    • Did not distinguish enzymatic from non-enzymatic contributions
  4. 2008 Medium

    Extended PRDX2's ROS-control role to immune effector regulation, linking it to TLR4/BAFF expression and allergic airway pathology.

    Evidence PrxII-null mouse splenocytes/macrophages, qRT-PCR, BAFF promoter assay, OVA-induced asthma model

    PMID:18442801

    Open questions at the time
    • Mechanism connecting ROS to TLR4/BAFF transcription unresolved
    • Single knockout model
  5. 2011 High

    Resolved PRDX2's tumor-suppressor function in AML and its epigenetic silencing, explaining how its loss enables ROS-driven leukemogenesis.

    Evidence ChIP-on-microarray for H3Ac, bisulfite sequencing, forced expression in bone marrow transplant mouse model with ROS measurement

    PMID:22207736

    Open questions at the time
    • Did not define which ROS-dependent c-Myc effectors are restrained
    • Did not address PRDX2 protein partners in myeloid cells
  6. 2011 Medium

    Defined the native oligomeric and complex states of PRDX2 and its stress-induced redistribution, linking quaternary structure to peroxidase function in erythrocytes.

    Evidence Proteomics, native PAGE, mass spectrometry and peroxidase assays on erythrocyte cytosol and membrane fractions

    PMID:21354257

    Open questions at the time
    • Functional consequence of catalase association not tested mechanistically
    • Membrane translocation trigger not isolated
  7. 2016 High

    Uncovered a non-enzymatic moonlighting function: PRDX2 directly inhibits HIF transcriptional activity in the nucleus, decoupling a signaling role from peroxidase chemistry.

    Evidence Reciprocal Co-IP, ChIP, nuclear fractionation and catalytic-site mutagenesis in hypoxic HeLa cells

    PMID:26837221

    Open questions at the time
    • Mechanism of nuclear translocation not defined
    • Structural basis of HIF-α binding unknown
  8. 2017 Medium

    Placed PRDX2 upstream of PI3K/AKT survival signaling and within a c-Myc/miR-200b-3p regulatory loop, framing its pro-tumor role in colon cancer.

    Evidence shRNA knockdown/overexpression with Western blotting, xenografts; luciferase miRNA target validation and c-Myc ChIP

    PMID:28432271 PMID:29258530

    Open questions at the time
    • Direct mechanism linking PRDX2 to AKT activation not defined
    • Whether AKT effect is enzymatic or via protein interaction untested
  9. 2018 High

    Established the kinetic basis for redox relay — PRDX2's slow resolution step lets its sulfenic intermediate form mixed disulfides with partner proteins, distinguishing it mechanistically from PRDX1.

    Evidence In vitro kinetics with recombinant PRDX1/PRDX2, intrinsic fluorescence and rate-constant determination for H2O2 and peroxynitrite

    PMID:30284335

    Open questions at the time
    • Specific physiological relay partners not identified in this assay
    • Cellular validation of mixed-disulfide transfer not shown
  10. 2018 Medium

    Connected PRDX2 to CDK2 and DNMT3A in myeloid cells, identifying physical interactions and regulatory inputs that modulate PRDX2 levels/activity to control differentiation and survival.

    Evidence Yeast 2-hybrid and Co-IP, knockdown/inhibitor studies, methylation analysis, xenograft/PDX models

    PMID:29720484 PMID:30245403

    Open questions at the time
    • Whether CDK2 phosphorylates PRDX2 not shown
    • Functional consequence of DNMT3A-PRDX2 binding beyond expression unclear
  11. 2019 High

    Revealed nuclear/DNA-damage roles: PRDX2 is recruited to double-strand breaks via REV7 and its expression is driven by NF-κB-p65 in infection, linking PRDX2 to genome-protective ROS control.

    Evidence Proteomics, reciprocal Co-IP, immunofluorescence, γH2AX foci; luciferase and ChIP for NF-κB-p65 with 8-oxoguanine/γH2AX assays in H. pylori models

    PMID:30657231 PMID:31536951

    Open questions at the time
    • Mechanism by which PRDX2 acts at DSBs not defined
    • Whether PRDX2 enzymatic activity is required at breaks untested
  12. 2020 Medium

    Positioned PRDX2 upstream of p38 MAPK/FOXO and autophagy/cell-cycle control in colorectal cancer, broadening its signaling reach.

    Evidence shRNA knockdown, electron microscopy, p38 activator rescue, xenograft model

    PMID:32692719

    Open questions at the time
    • Direct molecular link from PRDX2 to p38 activation not defined
    • Single cancer context
  13. 2021 Medium

    Identified a non-enzymatic oncogenic mechanism (RPL4 binding displacing MDM2 to degrade p53) and an extracellular exosomal function promoting osteoclastogenesis, expanding PRDX2 beyond intracellular antioxidant chemistry.

    Evidence Co-IP and competitive displacement assays for RPL4-MDM2-p53; exosome inhibition and recombinant PRDX2 osteoclast assays with anemia mouse model

    PMID:33587325 PMID:34117220

    Open questions at the time
    • Structural basis of RPL4 binding not resolved
    • Receptor/mechanism of extracellular PRDX2 osteoclast induction unknown
  14. 2023 Medium

    Linked PRDX2 to ferroptosis suppression via MFN2-dependent mitochondrial dynamics, defining a protective role in diabetic vascular dysfunction.

    Evidence Endothelial-specific PRDX2 overexpression in db/db mice with ACSL4/MFN2 manipulation and lipid peroxidation/iron assays

    PMID:36367849

    Open questions at the time
    • Direct biochemical interaction of PRDX2 with MFN2 not shown
    • Whether effect requires peroxidase activity untested
  15. 2025 Medium

    Showed PRDX2 drives EMT and metastasis in TNBC through PI3K/AKT-dependent SP1 activation of FN1, reinforcing its pro-metastatic role in solid tumors.

    Evidence RNA-seq, dual luciferase reporter, knockdown, Conoidin A inhibitor, xenograft model

    PMID:40217291

    Open questions at the time
    • Mechanism by which PRDX2 activates PI3K/AKT not resolved
    • Whether redox relay underlies SP1 activation untested

Open questions

Synthesis pass · forward-looking unresolved questions
  • The physiological redox-relay partners that receive PRDX2's mixed-disulfide signal in cells, and a unifying explanation for its opposing tumor-suppressor (AML) versus pro-tumor (solid cancer) roles, remain undefined.
  • No cellular redox-relay partner identified despite established kinetic capacity
  • Context-determinants of tumor-suppressor vs oncogenic behavior unknown
  • Structural models for non-enzymatic HIF-α and RPL4 binding lacking

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016209 antioxidant activity 5 GO:0016491 oxidoreductase activity 2 GO:0098772 molecular function regulator activity 2
Localization
GO:0005634 nucleus 2 GO:0005576 extracellular region 1 GO:0005829 cytosol 1
Pathway
R-HSA-162582 Signal Transduction 3 R-HSA-5357801 Programmed Cell Death 3 R-HSA-8953897 Cellular responses to stimuli 3
Partners
CATCDK2DNMT3AEPAS1HIF1AMDM2REV7RPL4
Complex memberships
PRDX2-catalase 440 kDa hetero-oligomerREV7-PRDX2 complex

Evidence

Reading pass · 22 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1995 TDPX1 (PRDX2) encodes an enzyme homologous to yeast thioredoxin-dependent peroxide reductase (thioredoxin peroxidase, TPX) and was mapped to human chromosome 13q12 by fluorescence in situ hybridization and somatic cell hybrid analysis. PCR amplification of human cDNA, somatic cell hybrid panel analysis, fluorescence in situ hybridization (FISH) Genomics Medium 7607688
2003 Down-regulation of PRDX2 in SH-SY5Y neuroblastoma cells via stable antisense transfection increased apoptosis under basal conditions and enhanced sensitivity to oxidative cytotoxic agents, demonstrating PRDX2's role in protecting neurons from reactive oxygen species. Stable antisense transfection, cell viability assays, comparison with SOD1 overexpression Cellular and molecular life sciences : CMLS Medium 12943237
2004 Deletion of the PrxII (PRDX2) gene in mice increases ROS levels in thymocytes, reduces apoptosis (hypodiploid cell formation), enlarges the thymus, and alters the SP/DP thymocyte ratio, establishing PRDX2 as a regulator of thymocyte development and proliferation through ROS control. PrxII-null mouse model, flow cytometry, dexamethasone and food restriction treatments, concanavalin A stimulation assay European journal of immunology High 15259009
2011 PRDX2 promoter has decreased histone H3 acetylation and DNA hypermethylation in AML, leading to low PRDX2 expression; forced PRDX2 expression inhibited c-Myc-induced leukemogenesis in vivo and reduced ROS generated in response to cytokines, identifying PRDX2 as an epigenetically silenced tumor suppressor in AML that limits ROS-driven myeloid cell growth. ChIP-on-microarray (H3Ac), bisulfite sequencing (DNA methylation), forced PRDX2 expression with bone marrow transplantation mouse model, ROS measurement Blood High 22207736
2011 In human erythrocytes, PRDX2 forms multiple oligomeric states (decamers and homo-polymers) in the cytosol and associates with catalase (CAT) in a 440 kDa hetero-oligomeric complex; upon oxidative stress (28-day storage), PRDX2 translocates to the membrane and forms cross-linked species with hemoglobin. Both the 440 kDa and 140 kDa complexes exhibit peroxidase activity. Proteomics, 2D gel electrophoresis, native PAGE, mass spectrometry, peroxidase activity assays on fractionated cytosol and membrane ghosts Biochimie Medium 21354257
2016 PRDX2 interacts with HIF-1α and HIF-2α in vitro and in hypoxic HeLa cells; prolonged hypoxia increases nuclear translocation of PRDX2, where it impairs HIF-1 and HIF-2 binding to hypoxia response elements of target genes, inhibiting their transcription. This effect is independent of PRDX2 enzymatic peroxidase activity. Co-immunoprecipitation, ChIP assay, nuclear fractionation, gene reporter assays, mutagenesis of catalytic site Oncotarget High 26837221
2017 PRDX2 knockdown in colon cancer cells reduces PI3K/AKT pathway activation (decreased p-AKT); PRDX2 overexpression increases p-AKT and alters Bcl-2/Bax ratio, placing PRDX2 upstream of the PI3K/AKT survival pathway in 5-FU chemoresistance. shRNA knockdown, Western blotting, in vivo xenograft model, immunohistochemistry correlation Bioscience reports Medium 28432271
2017 PRDX2 is a direct target of miR-200b-3p (validated by luciferase reporter assay); c-Myc represses miR-200b-3p transcription by binding its promoter (ChIP assay); PRDX2 overexpression rescues the suppressive effects of miR-200b-3p on CRC invasion, EMT, and chemoresistance, establishing a c-Myc/miR-200b-3p/PRDX2 regulatory loop. Luciferase reporter assay, ChIP assay, Western blotting, invasion assay, metastatic mouse model Journal of translational medicine Medium 29258530
2018 PRDX2 is a direct substrate/interactor of CDK2 in AML; CDK2 depletion leads to ubiquitin-dependent proteasomal degradation of CDK2 (mediated by E3 ligase KLHL6) and reactivates differentiation; CDK2 maintains its differentiation-blocking function at least in part by maintaining PRDX2 activity, establishing a CDK2-PRDX2 axis that blocks AML differentiation. Yeast 2-hybrid system, functional analyses, CDK2 knockdown/inhibitor studies, in vivo xenograft and PDX mouse models Blood Medium 29720484
2018 DNMT3A-R882H/C mutations upregulate PRDX2 expression through promoter hypomethylation, reducing ROS accumulation and impairing apoptosis. Both DNMT3A-WT and R882H/C mutants physically interact with PRDX2. Knockdown of PRDX2 from DNMT3A-mutant myeloid cells increases ROS, drug sensitivity, and apoptosis. Gene expression profiling, DNA methylation assay, PRDX2 knockdown, ROS measurement, co-immunoprecipitation Neoplasia (New York, N.Y.) Medium 30245403
2018 Differential kinetics between PRDX1 and PRDX2: the rate of disulfide formation (resolution step) is 11 s⁻¹ for PRDX1 vs 0.2 s⁻¹ for PRDX2, independent of oxidant. This slower resolution in PRDX2 allows its sulfenic acid intermediate to react with other protein thiols (forming mixed disulfides via the peroxidatic cysteine) to relay redox signals, whereas PRDX1 forms an intramolecular disulfide and continues the catalytic cycle. In vitro kinetic assays with recombinant human PRDX1 and PRDX2, intrinsic fluorescence measurements, rate constant determination for H2O2 and peroxynitrite reactions Protein science : a publication of the Protein Society High 30284335
2019 REV7 physically interacts with PRDX2 (validated by immunoprecipitation and immunofluorescence); the REV7-PRDX2 complex is augmented post-irradiation and assembles onto DNA double-strand breaks; REV7 knockdown disrupts nuclear PRDX2 localization post-irradiation, leading to increased oxidative stress and radiosensitization of esophageal cancer cells. Proteomic analysis of REV7-interacting proteins, co-immunoprecipitation, immunofluorescence, γH2AX focus assay, ROS measurement, xenograft model Cancer science Medium 30657231
2019 NF-κB-p65 directly binds the PRDX2 promoter (confirmed by luciferase reporter and ChIP assays) and drives PRDX2 upregulation in response to H. pylori infection; PRDX2 knockdown increases ROS, oxidative DNA damage (8-oxoguanine), and double-strand breaks (γ-H2AX), and sensitizes gastric cancer cells to cisplatin. Luciferase reporter assay, ChIP assay, H2DCFDA ROS assay, 8-oxoguanine immunostaining, γ-H2AX detection, in vitro and in vivo H. pylori infection models Redox biology High 31536951
1999 Silica treatment triggers rapid degradation of PrxII (PRDX2) in Rat2 cells through a Ca²⁺-dependent protease (likely calpain), independent of ROS and proteasomal activity (insensitive to MG132 and lactacystin), thereby aggravating cellular oxidative stress. Western blotting, protease inhibitor studies (MG132, lactacystin), Ca²⁺ ionophore treatment, NAC and DPI inhibitor experiments Biochemical and biophysical research communications Medium 10558905
2008 In PrxII-null mouse splenocytes and macrophages, TLR4 protein is decreased compared to wild-type, and BAFF expression and BAFF promoter activity are elevated. PrxII-null mice show more severe airway hyper-responsiveness in OVA-induced asthma. This establishes PRDX2 as a regulator of TLR4 and BAFF expression through ROS control. PrxII-null mouse model, real-time quantitative RT-PCR, BAFF promoter activity assay, airway hyper-responsiveness measurements, eosinophil and IgE quantification International immunopharmacology Medium 18442801
2021 PRDX2 binds RPL4 (ribosomal protein L4), reducing the interaction between RPL4 and MDM2; this leads to increased MDM2-mediated ubiquitination and degradation of p53, thereby promoting colorectal cancer cell proliferation. PRDX2 thus acts as an oncogenic regulator of the RPL4-MDM2-p53 axis. Co-immunoprecipitation, Western blotting, PRDX2 knockdown and overexpression, proliferation assays Cell death & disease Medium 34117220
2021 PRDX2 is released by erythroid cells in exosomes; inhibiting exosomal release significantly decreases the osteoclastogenic capacity of erythroid conditioned medium. Recombinant PRDX2 directly induces osteoclast formation from RANKL-primed precursors to levels comparable to continuous RANKL treatment, establishing an extracellular/exosomal function of PRDX2 in promoting osteoclastogenesis. Immunoblotting, mass spectrometry, exosomal inhibitor treatment, recombinant PRDX2 addition to RAW264.7 and primary bone marrow precursors, phlebotomy-induced anemia mouse model Physiological reports Medium 33587325
2020 PRDX2 removal in colorectal cancer cells inhibits S-phase progression and activates p38 MAPK, leading to autophagy flux disruption. The p38 MAPK activator partially rescues the cell-cycle and autophagy phenotypes of PRDX2 knockdown, placing PRDX2 upstream of p38 MAPK/FOXO signaling in CRC cell-cycle and autophagy regulation. shRNA knockdown, electron microscopy, immunostaining, Western blotting, p38 activator rescue experiment, xenograft model Aging Medium 32692719
2022 PRDX2 knockdown in colorectal cancer cells sensitizes them to dihydroartemisinin (DHA) by increasing ROS levels; mechanistically, DHA inhibits PRDX2 expression to elevate ROS, which activates ER stress, STAT3, JNK, and p38 signaling pathways, enhancing the anti-tumor activity of oxaliplatin. PRDX2 knockdown, ROS measurement, Western blotting, flow cytometry, in vivo mouse xenograft model Phytomedicine : international journal of phytotherapy and phytopharmacology Low 35104762
2022 Oxiconazole downregulates PRDX2 protein levels, leading to ROS accumulation that inactivates the Akt/mTOR pathway and inhibits RAB7A-mediated autophagosome-lysosome fusion, causing autophagy arrest and CRC cell death. Overexpression of PRDX2 significantly impedes oxiconazole-induced autophagy arrest. PRDX2 overexpression rescue, Western blotting, flow cytometry, Akt/mTOR pathway analysis, RAB7A colocalization assay International journal of biological sciences Medium 35813474
2023 PRDX2 was identified as a downstream target of isorhapontigenin (ISO) in diabetic cardiac microvascular dysfunction; endothelial-specific overexpression of PRDX2 inhibits ferroptosis by suppressing oxidative stress, iron overload, and lipid peroxidation. PRDX2 mediates its anti-ferroptotic effect via MFN2-dependent mitochondrial dynamics, and MFN2 overexpression suppresses mitochondrial translocation of ACSL4, inhibiting mitochondria-associated ferroptosis. Endothelial-specific PRDX2 overexpression in db/db mice, ACSL4/MFN2 overexpression/knockdown, lipid peroxidation and iron measurements, mitochondrial function assays Diabetes Medium 36367849
2025 PRDX2 activates the PI3K/AKT signaling pathway to enhance SP1 binding to the FN1 promoter (confirmed by dual luciferase reporter assay), driving FN1 expression and promoting TNBC cell migration, invasion, and EMT. RNA sequencing, Western blotting, dual luciferase reporter assay, PRDX2 knockdown, in vivo xenograft model, Conoidin A PRDX2 inhibitor treatment Journal of translational medicine Medium 40217291

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1999 Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1416 10490031
2018 Mapping 3D genome organization relative to nuclear compartments using TSA-Seq as a cytological ruler. The Journal of cell biology 325 30154186
2008 Sessile serrated adenoma (SSA) vs. traditional serrated adenoma (TSA). The American journal of surgical pathology 246 18162766
2021 CircDIDO1 inhibits gastric cancer progression by encoding a novel DIDO1-529aa protein and regulating PRDX2 protein stability. Molecular cancer 138 34384442
2023 Isorhapontigenin Attenuates Cardiac Microvascular Injury in Diabetes via the Inhibition of Mitochondria-Associated Ferroptosis Through PRDX2-MFN2-ACSL4 Pathways. Diabetes 100 36367849
2003 Gfi-1 attaches to the nuclear matrix, associates with ETO (MTG8) and histone deacetylase proteins, and represses transcription using a TSA-sensitive mechanism. Journal of cellular biochemistry 100 12874834
2019 PRDX2 protects against oxidative stress induced by H. pylori and promotes resistance to cisplatin in gastric cancer. Redox biology 96 31536951
1992 Diversity of immunodominant 56-kDa type-specific antigen (TSA) of Rickettsia tsutsugamushi. Sequence and comparative analyses of the genes encoding TSA homologues from four antigenic variants. The Journal of biological chemistry 95 1618776
2002 Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice. Infection and immunity 91 12010969
2018 Ubiquitin-dependent degradation of CDK2 drives the therapeutic differentiation of AML by targeting PRDX2. Blood 86 29720484
2021 Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE) Study. Journal for immunotherapy of cancer 82 34266881
2002 Induction and superinduction of growth arrest and DNA damage gene 45 (GADD45) alpha and beta messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells. Cancer letters 82 12406558
2017 Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells. Cellular oncology (Dordrecht, Netherlands) 81 28160167
2011 Genome-wide analysis of histone H3 acetylation patterns in AML identifies PRDX2 as an epigenetically silenced tumor suppressor gene. Blood 76 22207736
2015 Protein-ligand interactions investigated by thermal shift assays (TSA) and dual polarization interferometry (DPI). Acta crystallographica. Section D, Biological crystallography 71 25615858
2020 Tyramide signal amplification mass spectrometry (TSA-MS) ratio identifies nuclear speckle proteins. The Journal of cell biology 67 32609799
2006 Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells. International journal of oncology 65 16773209
2005 Effects of Histone Deacetylase Inhibitor (HDACi); Trichostatin-A (TSA) on the expression of housekeeping genes. Molecular and cellular probes 57 16326072
2017 Disruption of the c-Myc/miR-200b-3p/PRDX2 regulatory loop enhances tumor metastasis and chemotherapeutic resistance in colorectal cancer. Journal of translational medicine 55 29258530
2012 TSA suppresses miR-106b-93-25 cluster expression through downregulation of MYC and inhibits proliferation and induces apoptosis in human EMC. PloS one 53 23028803
2019 TSA-CRAFT: A Free Software for Automatic and Robust Thermal Shift Assay Data Analysis. SLAS discovery : advancing life sciences R & D 48 30744467
2003 Peroxiredoxin 2 (PRDX2), an antioxidant enzyme, is under-expressed in Down syndrome fetal brains. Cellular and molecular life sciences : CMLS 48 12943237
1995 Modulation of TCR-mediated signaling pathway by thymic shared antigen-1 (TSA-1)/stem cell antigen-2 (Sca-2). Journal of immunology (Baltimore, Md. : 1950) 48 7499840
2018 Differential parameters between cytosolic 2-Cys peroxiredoxins, PRDX1 and PRDX2. Protein science : a publication of the Protein Society 42 30284335
2004 Reactive oxygen species induced by the deletion of peroxiredoxin II (PrxII) increases the number of thymocytes resulting in the enlargement of PrxII-null thymus. European journal of immunology 42 15259009
2021 PRDX2 promotes the proliferation of colorectal cancer cells by increasing the ubiquitinated degradation of p53. Cell death & disease 41 34117220
2015 Combination of HDAC inhibitor TSA and silibinin induces cell cycle arrest and apoptosis by targeting survivin and cyclinB1/Cdk1 in pancreatic cancer cells. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 41 26349994
2011 Proteomic analysis of psoriatic skin tissue for identification of differentially expressed proteins: up-regulation of GSTP1, SFN and PRDX2 in psoriatic skin. International journal of molecular medicine 40 21805023
2020 Peroxiredoxin2 (Prdx2) Reduces Oxidative Stress and Apoptosis of Myocardial Cells Induced by Acute Myocardial Infarction by Inhibiting the TLR4/Nuclear Factor kappa B (NF-κB) Signaling Pathway. Medical science monitor : international medical journal of experimental and clinical research 39 33268762
2011 Oxidative stress-dependent oligomeric status of erythrocyte peroxiredoxin II (PrxII) during storage under standard blood banking conditions. Biochimie 38 21354257
2017 Knockdown of PRDX2 sensitizes colon cancer cells to 5-FU by suppressing the PI3K/AKT signaling pathway. Bioscience reports 37 28432271
1997 Peroxidase activity of a TSA-like antioxidant protein from a pathogenic amoeba. Free radical biology & medicine 37 9378375
2018 Production of recombinant TSA-1 and evaluation of its potential for the immuno-therapeutic control of Trypanosoma cruzi infection in mice. Human vaccines & immunotherapeutics 36 30192702
2012 P53-dependent antiproliferative and pro-apoptotic effects of trichostatin A (TSA) in glioblastoma cells. Journal of neuro-oncology 36 22270849
2007 HDAC inhibitors TSA and sodium butyrate enhanced the human IL-5 expression by altering histone acetylation status at its promoter region. Immunology letters 36 17270283
2016 PRDX2 and PRDX4 are negative regulators of hypoxia-inducible factors under conditions of prolonged hypoxia. Oncotarget 35 26837221
2019 REV7 confers radioresistance of esophagus squamous cell carcinoma by recruiting PRDX2. Cancer science 34 30657231
2018 Trypanosoma cruzi vaccine candidate antigens Tc24 and TSA-1 recall memory immune response associated with HLA-A and -B supertypes in Chagasic chronic patients from Mexico. PLoS neglected tropical diseases 34 29377898
2015 Synergistic anticancer effects of cisplatin and histone deacetylase inhibitors (SAHA and TSA) on cholangiocarcinoma cell lines. International journal of oncology 34 26575528
2008 TSA downregulates Wilms tumor gene 1 (Wt1) expression at multiple levels. Nucleic acids research 33 18535006
2015 Traditional serrated adenoma (TSA): morphological questions, queries and quandaries. Journal of clinical pathology 32 26553935
2014 Oral and intraperitoneal administration of quercetin decreased lymphocyte DNA damage and plasma lipid peroxidation induced by TSA in vivo. BioMed research international 31 24868531
2009 Increased liver protein and mRNA expression of natural killer cell-enhancing factor B (NKEF-B) in ayu (Plecoglossus altivelis) after Aeromonas hydrophila infection. Fish & shellfish immunology 31 19340957
2006 Three in one: TSA, TSA', and SA units in one crystal structure of a yttrium(III) complex with a monophosphinated H4dota analogue. Inorganic chemistry 31 16562966
2005 Melanoma cell lines are susceptible to histone deacetylase inhibitor TSA provoked cell cycle arrest and apoptosis. Pigment cell research 31 15892716
2020 PRDX2 Promotes the Proliferation and Metastasis of Non-Small Cell Lung Cancer In Vitro and In Vivo. BioMed research international 30 32908916
2022 Dihydroartemisinin enhances the anti-tumor activity of oxaliplatin in colorectal cancer cells by altering PRDX2-reactive oxygen species-mediated multiple signaling pathways. Phytomedicine : international journal of phytotherapy and phytopharmacology 29 35104762
2008 Structure, organization and expression of common carp (Cyprinus carpio L.) NKEF-B gene. Fish & shellfish immunology 29 19032984
2011 Sp1 is a transcription repressor to stanniocalcin-1 expression in TSA-treated human colon cancer cells, HT29. Journal of cellular biochemistry 28 21465530
1998 Detection of oestrogen receptors in non-invasive and invasive transitional cell carcinomas of the urinary bladder using both conventional immunohistochemistry and the tyramide staining amplification (TSA) technique. The Journal of pathology 27 9924432
2019 Role of peroxiredoxin of the AhpC/TSA family in antioxidant defense mechanisms of Francisella tularensis. PloS one 26 30870480
1995 Localization of TDPX1, a human homologue of the yeast thioredoxin-dependent peroxide reductase gene (TPX), to chromosome 13q12. Genomics 26 7607688
2024 Implications and progression of peroxiredoxin 2 (PRDX2) in various human diseases. Pathology, research and practice 25 38219498
2020 STVNa Attenuates Isoproterenol-Induced Cardiac Hypertrophy Response through the HDAC4 and Prdx2/ROS/Trx1 Pathways. International journal of molecular sciences 25 31968660
2018 Genetic and Epigenetic Perturbations by DNMT3A-R882 Mutants Impaired Apoptosis through Augmentation of PRDX2 in Myeloid Leukemia Cells. Neoplasia (New York, N.Y.) 25 30245403
2016 PRDX2 protects hepatocellular carcinoma SMMC-7721 cells from oxidative stress. Oncology letters 25 27602166
2012 Enhancement of immune response induced by DNA vaccine cocktail expressing complete LACK and TSA genes against Leishmania major. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 25 23030526
2011 Autotaxin is induced by TSA through HDAC3 and HDAC7 inhibition and antagonizes the TSA-induced cell apoptosis. Molecular cancer 25 21314984
2015 Functional and structural changes in plant mitochondrial PrxII F caused by NO. Journal of proteomics 24 25682994
2012 ERK inhibition enhances TSA-induced gastric cancer cell apoptosis via NF-κB-dependent and Notch-independent mechanism. Life sciences 24 22781708
2023 EGCG, GCG, TFDG, or TSA Inhibiting Melanin Synthesis by Downregulating MC1R Expression. International journal of molecular sciences 23 37446194
2020 PRDX2 removal inhibits the cell cycle and autophagy in colorectal cancer cells. Aging 23 32692719
2020 Long Non-coding RNA CASC15 Promotes Intrahepatic Cholangiocarcinoma Possibly through Inducing PRDX2/PI3K/AKT Axis. Cancer research and treatment 23 33017884
2019 TSA restores hair follicle-inductive capacity of skin-derived precursors. Scientific reports 23 30814580
2017 PRDX2 in Myocyte Hypertrophy and Survival is Mediated by TLR4 in Acute Infarcted Myocardium. Scientific reports 23 28765537
1998 Characterization and mapping to human chromosome 8q24.3 of Ly-6-related gene 9804 encoding an apparent homologue of mouse TSA-1. Journal of immunology (Baltimore, Md. : 1950) 23 9551972
2020 PRDX2 plays an oncogenic role in esophageal squamous cell carcinoma via Wnt/β-catenin and AKT pathways. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 22 32130676
2019 Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model. Cancers 22 31783695
2005 Trichostatin A (TSA) sensitizes the human prostatic cancer cell line DU145 to death receptor ligands treatment. Cancer biology & therapy 22 15846101
2003 Differential effects of trichostatin A on gelatinase A expression in 3T3 fibroblasts and HT-1080 fibrosarcoma cells: implications for use of TSA in cancer therapy. Biochemical and biophysical research communications 22 12604329
2021 The triterpenoid ursolic acid ameliorates stress in Caenorhabditis elegans by affecting the depression-associated genes skn-1 and prdx2. Phytomedicine : international journal of phytotherapy and phytopharmacology 21 34111615
2021 Discovery of the SMYD3 Inhibitor BAY-6035 Using Thermal Shift Assay (TSA)-Based High-Throughput Screening. SLAS discovery : advancing life sciences R & D 21 34154424
2014 Expression pattern of the PRDX2, RAB1A, RAB1B, RAB5A and RAB25 genes in normal and cancer cervical tissues. International journal of oncology 21 25339198
2022 VPA and TSA Interrupt the Interplay between mutp53 and HSP70, Leading to CHK1 and RAD51 Down-Regulation and Sensitizing Pancreatic Cancer Cells to AZD2461 PARP Inhibitor. International journal of molecular sciences 20 35216385
2022 Repurposing Oxiconazole against Colorectal Cancer via PRDX2-mediated Autophagy Arrest. International journal of biological sciences 20 35813474
2018 Global analysis of erythroid cells redox status reveals the involvement of Prdx1 and Prdx2 in the severity of beta thalassemia. PloS one 20 30521599
2014 Neuroprotective capabilities of TSA against cerebral ischemia/reperfusion injury via PI3K/Akt signaling pathway in rats. The International journal of neuroscience 19 24730998
2014 Prevention of Pulmonary Fibrosis via Trichostatin A (TSA) in Bleomycin Induced Rats. Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG 19 25363222
2001 Tyramide signal amplification (TSA) systems for the enhancement of ISH signals in cytogenetics. Current protocols in cytometry 19 18770747
1983 Cell growth and differentiation in vitro in mouse macrophages transformed by a tsA mutant of simian virus 40. I. Cellular response in proliferative and phagocytic activities to the shift of temperature differs depending on the culture state in mouse bone marrow cells transformed by the tsA640 mutant of simian virus 40. Journal of cellular physiology 19 6309870
2021 PRDX2 Protects Against Atherosclerosis by Regulating the Phenotype and Function of the Vascular Smooth Muscle Cell. Frontiers in cardiovascular medicine 18 33791345
2014 Short-term use of telmisartan attenuates oxidation and improves Prdx2 expression more than antioxidant β-blockers in the cardiovascular systems of spontaneously hypertensive rats. Hypertension research : official journal of the Japanese Society of Hypertension 18 25319599
2014 Mapping of single-copy genes by TSA-FISH in the codling moth, Cydia pomonella. BMC genetics 18 25471491
2006 [Histone-deacetylases inhibitors: from TSA to SAHA]. Bulletin du cancer 18 16455503
2006 TSA-induced cell death in prostate cancer cell lines is caspase-2 dependent and involves the PIDDosome. Cancer biology & therapy 18 17110788
2023 Overexpression of PRDX2 in Adipose-Derived Mesenchymal Stem Cells Enhances the Therapeutic Effect in a Neurogenic Erectile Dysfunction Rat Model by Inhibiting Ferroptosis. Oxidative medicine and cellular longevity 17 36819780
2019 Prdx2 Upregulation Promotes the Growth and Survival of Gastric Cancer Cells. Pathology oncology research : POR 16 31807984
2017 Alterations in NO/ROS ratio and expression of Trx1 and Prdx2 in isoproterenol-induced cardiac hypertrophy. Acta biochimica et biophysica Sinica 15 29036266
2006 Synthesis and evaluation of [125I]I-TSA as a brain nicotinic acetylcholine receptor alpha7 subtype imaging agent. Nuclear medicine and biology 15 16631079
2019 Effects of the Prdx2 depletion on blood pressure and life span in spontaneously hypertensive rats. Hypertension research : official journal of the Japanese Society of Hypertension 14 30655626
2021 Active hematopoiesis triggers exosomal release of PRDX2 that promotes osteoclast formation. Physiological reports 13 33587325
2018 Epigenetic silencing of the tumor suppressor genes SPI1, PRDX2, KLF4, DLEC1, and DAPK1 in childhood and adolescent lymphomas. Pediatric hematology and oncology 13 30020823
2017 Immunogenicity and efficacy of a bivalent DNA vaccine containing LeIF and TSA genes against murine cutaneous leishmaniasis. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 13 28233451
2016 Cloning and characterization of indole synthase (INS) and a putative tryptophan synthase α-subunit (TSA) genes from Polygonum tinctorium. Plant cell reports 13 27585574
2013 Transcription factor Sox4 is required for PUMA-mediated apoptosis induced by histone deacetylase inhibitor, TSA. Biochemical and biophysical research communications 13 23916609
2008 Differential role of peroxiredoxin II (PrxII) on the expression of toll-like receptor 4 (TLR4) and B-cell activating factor (BAFF) in ovalbumin (OVA)-induced mouse asthma. International immunopharmacology 13 18442801
1999 Rapid degradation of PrxI and PrxII induced by silica in Rat2 cells. Biochemical and biophysical research communications 13 10558905
2020 Silencing of PRDX2 Inhibits the Proliferation and Invasion of Non-Small Cell Lung Cancer Cells. BioMed research international 12 32337219
2013 Upregulation of phosphorylated HSP27, PRDX2, GRP75, GRP78 and GRP94 in acquired middle ear cholesteatoma growth. International journal of molecular sciences 12 23852020
2025 Targeting PRDX2 to inhibit tumor growth and metastasis in triple-negative breast cancer: the role of FN1 and the PI3K/AKT/SP1 pathway. Journal of translational medicine 11 40217291

Missed literature

Know a paper Affinage missed for PRDX2? Flag it for the maintainers and the community.

No submissions yet.